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motor neuron disease. SMA is caused by mutations in the
survival motor neuron gene (SMN1), leading to reduced
levels of SMN protein in the CNS. The actin-binding protein
plastin 3 (PLS3) has been reported as a modiﬁer for SMA,
making it a potential therapeutic target. Here, we show
reduced levels of PLS3 protein in the brain and spinal cord
of a mouse model of SMA. Our study also revealed that len-
tiviral-mediated PLS3 expression restored axonal length in
cultured Smn-deﬁcient motor neurons. Delivery of adeno-
associated virus serotype 9 (AAV9) harboring Pls3 cDNA
via cisterna magna in SMND7 mice, a widely used animal
model of SMA, led to high neuronal transduction efﬁciency.
PLS3 treatment allowed a small but signiﬁcant increase of
lifespan by 42%. Although there was no improvement of
phenotype, this study has demonstrated the potential use
of Pls3 as a target for gene therapy, possibly in combination
with other disease modiﬁers.Received 31 October 2017; accepted 15 January 2018;
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Spinal muscular atrophy (SMA) is a recessive, monogenic motor
neuron disease carried by approximately 1/40 people, and account-
ing for 1/6,000 to 1/10,000 live births. The most common form,
SMA type I, manifests within 6 months of birth as a progressive
dystonia, beginning at the lower extremities and progressing in-
ward. Death generally occurs at around 18 months due to respira-
tory complications, a result of weakened intercostal muscles. The
disease is caused by homozygous deletion of survival of motor
neuron (SMN1) gene, which encodes a 294-aa protein implicated
in RNA splicing (as part of the small nuclear ribonucleoprotein
[snRNP] complex), stabilization of the axonal growth cone in neu-
rons, and the formation of neuromuscular junctions. Disease
severity correlates with patients’ copy number of SMN2, an in-
verted set of repeats of SMN1 with a single mutation that results
in 90% of its translated product being truncated and non-func-
tional. However, families with identical SMN2 copy numbers
may have radically different disease severity implying that addi-
tional factors must contribute to the rescue of homozygous
SMN1 deletion.Molecular Therapy: Methods
This is an open access article under the CC BY-NCA transcriptome-wide differential expression analysis performed on
total RNA from lymphoblastoid cells taken from SMN1-deleted
siblings with discordant disease outcomes revealed a signiﬁcant asso-
ciation between disease severity and Plastin 3 (PLS3) expression.1
Further analysis of blood samples from a diverse population of
SMA patients and from healthy controls conﬁrmed this association.1
Stratiﬁed analysis of blood samples from SMA type I, II, and III pa-
tients demonstrated that postpubertal females only show an inverse
correlation between circulating Pls3 and SMA severity, suggesting a
role for PLS3 as an age and sex speciﬁc modiﬁer of SMA. It has
been suggested that this sex-speciﬁc effect may be due to PLS3 map-
ping to Xq23.2
In smn/ zebraﬁsh model, Pls3 mRNA splicing and protein stability
are unaffected, but Pls3 protein levels overall are reduced. Partially
restoring PLS3 in these animals rescued presynaptic defects and mo-
tor behavior, suggesting that PLS3 is not merely a correlate of SMN
expression, but instead plays a signiﬁcant role in SMA pathology.
PLS3 orthologs act as SMN modiﬁer genes in Caenorhabditis elegans
and Drosophila, possibly involving pathways of endocytosis and RNA
processing.3
Investigations into the function of PLS3 have begun to shed light on
its role in protecting against SMA. Removal of PLS3’s ability to bind
to or cross-link actin ﬁlaments, by deleting one or both of its acting
binding domains (ABD1/2), did not fully prevent the molecule
from rescuing smn/ mutant zebraﬁsh. This suggests that PLS3’s
role might involve an additional function unrelated to its interaction
with actin. Further deletion studies determined that the EF hand
motifs and speciﬁcally their interaction with Ca2+ ions are essential
for PLS3 function in motor neuron development.4 This is supported
by the observation in SMA of calcium dysregulation in the growth
cone during motor axon outgrowth.5& Clinical Development Vol. 9 June 2018 ª 2018 The Author(s). 81
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Plastin 3 Protein Levels in Postnatal Day
1, 5, and 10 SMND7 Mice
Representative images of western blot and fold changes
in PLS3 protein levels in brain, spinal cord, and muscle
tissues fromwild-type (WT), carrier littermates (HEMI), and
SMND7 (KO) postnatal day 1 (P1) (A and B), P5 (C and D),
and P10 (E and F) neonate mouse pups (n = 3). The
membrane was probed with mouse anti-PLS3 antibody;
GAPDH was used as the house keeping control (n = 3).
Error bars represent SEM. One-way ANOVA *p < 0.05,
**p < 0.01, ***p < 0.001.
Molecular Therapy: Methods & Clinical DevelopmentIn the present study, we assess the expression pattern of PLS3 in
SMND7, a well-characterized mouse model of SMA,6 as well as eval-
uate the neuroprotective effect of lentiviral gene transfer of Pls3 in an
in vitro model of SMA (puriﬁed motor neurons). We provide evi-
dence that PLS3 is important for axonogenesis, since its overexpres-82 Molecular Therapy: Methods & Clinical Development Vol. 9 June 2018sion rescued the axon length and outgrowth de-
fects associated with Smn depletion in motor
neurons derived from SMND7 embryos.
AAV9-mediated Pls3 gene delivery in SMND7
through cisterna magna led to efﬁcient gene
transfer to motor neurons and marginally
extended mouse survival.
RESULTS
PLS3 Expression in SMA Mouse Model
The severity of SMA is determined primarily by
levels of SMN protein produced from SMN2
copy of the gene.5,7 Discordant families have
also been described in which siblings have the
same genetics but present with different pheno-
types, with some siblings affected and others un-
affected.8 This suggests that disease modiﬁers
other than SMN may exist. A transcriptome-
wide differential expression analysis performed
on total RNA from lymphoblastoid cells taken
from SMN1-deleted siblings with discordant
disease outcomes revealed a signiﬁcant associa-
tion between disease severity and PLS3 expres-
sion. PLS3, an actin-binding and bundling
protein, was identiﬁed as a protective modiﬁer
of SMA.1 Here, we assessed Pls3 levels within
the brain, spinal cord, and muscle of the
SMND7 mice (SMN2+/+, SMND7+/+, smn/;
deﬁned as knockout [KO]) compared to their
wild-type (SMN2+/+, SMND7+/+, smn+/+) and
carrier (SMN2+/+, SMND7+/+, smn+/) litter-
mates at postnatal days 1, 5, and 10 (P1, P5,
and P10) (n = 3). Proteins were extracted and
PLS3 expression measured by western blot.
Upon analysis at postnatal day 1, we observed
no statistically signiﬁcant difference between
genotypes for PLS3 protein levels in the brain,spinal cord, or in thighmuscle (Figures 1A and 1B). None of the geno-
types showed detectable PLS3 protein in muscle and only low detec-
tion in the spinal cord (Figures 1A and 1B). This suggests that Smn
deﬁciency does not appear to affect PLS3 levels at P1. There was no
discernible difference between protein levels in any of the genotypes
Figure 2. PLS3 Immunoreactivity in the Brain and Spinal Cord Sections of
WT and KO P10 Pups
(A) Immunohistochemical staining showing PLS3 expression in the brain from P10
wild-type (WT) and SMND7 mice (KO) (n = 3 per group). Brain sections from WT
showing immune reactivity of PLS3 associated with a large number of neurons in the
brain cortex (brown) (arrows). SMND7 mice (KO) brain sections showed reduced
reactivity of PLS3 associated with neurons (arrows). Scale bar, 50 mm. PLS3
immunoreactivity in the cervical (B) and lumbar (C) spinal cord from P10 wild-type
(WT) and SMND7 (KO) mice (n = 3). WT spinal cord sections showing PLS3
immuno-reactivity in large number of neurons in the ventral horn of the spinal cord
(brown) (arrows), when compared to sections from SMND7 mice KO section,
which showed minimal reactivity of PLS3 associated with neurons (arrows). Scale
bar, 50 mm.
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Molecat this age, which correlates with the lack of phenotype in P1 pups.
Based on the general appearance and measurement of body weight,
the KO pups were phenotypically indistinguishable from theirWT lit-
termates in the ﬁrst 48 hr after birth. PLS3 protein levels showed no
signiﬁcant difference in the P5 brains of all genotypes (Figure 1C).
However, the current analysis revealed that Pls3 protein levels were
signiﬁcantly lower in P5 spinal cord of KO and carriers when
compared toWT (p < 0.05, n = 3) (Figures 1C and 1D). PLS3 was un-
detectable in muscle of the 3 groups tested (Figures 1C and 1D).
Western blot analysis performed at postnatal day 10 revealed a signif-
icant decline of Pls3 protein levels in the KO brain compared to pre-
vious time points (P1 and P5) and the same tissues in carriers andWT
(Figures 1E and 1F), suggesting that Smn levels did affect PLS3
expression at P10 in the brain. It is also noteworthy to state the signif-
icant reduction of PLS3 protein in spinal cord of carrier pups (Figures
1E and 1F). Surprisingly PLS3 levels were higher in brains of carrier
littermates compared to WT (Figures 1E and 1F).
Having established that PLS3 protein is depleted in the brain, spinal
cord, andmuscle tissues from P10 Smn-deﬁcient mice, we next set out
to conﬁrm the western blot ﬁndings by carrying out qualitative histo-
logical analysis. Consistent with western blotting data (Figures 1E
and 1F), immunolabeling of brain and spinal cord sections with
anti-PLS3 antibodies revealed reduction in PLS3 staining in P10
KO animals compared to WT group (Figure 2).
PLS3 Overexpression Promotes Motor Neuron Axonal Growth
We report here (Figures 1 and 2) that PLS3 is downregulated in the
CNS of Smn-deﬁcient mouse model, suggesting an important role
of Pls3 in neurodegeneration associated with SMA. To test whether
overexpression of PLS3 would prevent neurodegenerative phenotype,
we constructed a lentiviral (LV) harboring human Pls3 cDNA and
tested its efﬁciency in an in vitro model of SMA. We ﬁrst assured
that the generated LV vector can produce PLS3 protein in vitro in a
neuronal-like cell line, NSC34 cells. Cells were transduced with
LV-PLS3 vector at different MOIs of 5, 10, 20, 40, and 80. The western
blot revealed the presence of a 70-kDa band representing the PLS3
protein (Figure 3A). Analysis of the dose response indicated a positive
correlation between PLS3 expression and the MOI (Figure 3B). The
transduced cells showed no overt signs of toxicity, as indicated by aular Therapy: Methods & Clinical Development Vol. 9 June 2018 83
Figure 3. Lentiviral-Mediated Pls3 Expression Rescues Axonal Deficit in Smn-Deficient Motor Neurons
(A) Western blot showing NSC34 cells transduced with LV-PLS3 at MOI 5, 10, 20, 40, or 80 and probed with anti-human PLS3 antibody; a-tubulin was the loading control
(n = 3). Untransduced (UT) cells were considered as negative control. (B) A dose-response curve of LV-Pls3 at 5 days posttransduction, along with fold change in Pls3 protein
levels for each MOI used. (C) Motor neurons isolated from E13wild-type (WT), carrier (HEMI), and SMND7 (KO) embryos were transduced with LV-Pls3 or LV-GFP at MOI 80.
Cells were labeled for Pls3 (blue), tubulin (red), or GFP (green). Scale bars, 20 mm. (D) Impact of LV-Pls3 treatment on axonal length in Smn-deficient motor neurons. The bar
chart shows the effect of LV-Pls3 treatment on axonal length in wild-type, carrier (HEMI), and SMN knockout (KO) embryos. One-way ANOVA (*p < 0.05, ***p < 0.001) was
considered to be statistically significant. Data generated from four independent experiments (n = 4). Average neurite lengths ± SEM (n = 100 neurites).
Molecular Therapy: Methods & Clinical Developmentchange in cell morphology, reduced adherence or presence of dead
cells, or obvious difference in growth rate even when the viral vector
was used at higher MOI.
To objectively quantify the impact of PLS3 on the neurodegenerative
phenotype reported in SMAmotor neurons in vitro, we measured neu-
rite length in Smn-deﬁcient motor neurons.9 Enriched spinal motor
neurons derived from E13 SMND7 embryos and cultured using the
p75 immunopanning method10 were used to assess the impact of LV-
PLS3 transduction (MOI 80). Motor neurons were visualized down
themicroscope and cell included in the analysis if the entire axon length
could be seen in a single ﬁeld. One hundred cells were imaged for each
genotype and ImageJwas used todrawa line from the start of the axonat
the cell body to the tip of the axon. In the case of axons with branches
(Figure 3C), the thickest and longest branch was chosen as the main
axon, and other branches were excluded from length calculations.
Consistent with previous reports,1,9 our in vitro study showed a sig-
niﬁcant reduction in axon length of Smn-deﬁcient motor neurons84 Molecular Therapy: Methods & Clinical Development Vol. 9 June 201when compared to cells from either WT or carrier embryos (Fig-
ure 3D; p < 0.001). Our studies revealed that overexpression of
PLS3 through LV led to a signiﬁcant rescue (p < 0.001) of average
axon length and outgrowth defects associated with Smn downregula-
tion (n = 100) (Figures 3C and 3D). Expression of PLS3 in carrier
and wild-type motor neurons also signiﬁcantly increased axon length
(p < 0.05). As expected, the GFP control virus showed no effect on
axon length in any genotype. Our data revealed that PLS3 can rescue
motor neuron (MN) axon deﬁcits reported in SMND7 primary MNs,
providing evidence that PLS3 is important for axonogenesis.
AAV9-Mediated PLS3 Gene Therapy in SMND7 Mouse Model
of SMA
We next evaluated the neuroprotective ability of AAV9 encoding
PLS3 in a mouse model (SMND7) of SMA. AAV9-Pls3 virus was
tested in P1 carrier pups prior efﬁcacy study in SMND7 mice. Four
weeks after cisterna magna AAV9-GFP or AAV9-Pls3 vector deliv-
ery, animals were culled and spinal cord was collected for transgene
assessment. PLS3 expression was assessed into the three different8
Figure 4. AAV9-Mediated Gene Therapy in SMA Mouse Model
(A) Western blot analysis of the spinal cord following cisterna magna delivery of AAV9-Pls3. PLS3 protein levels in three parts of the spinal cord; cervical (C), thoracic (T), and
lumbar (L) of carrier (HEMI) pups 4weeks postdelivery of AAV9-GFP or AAV9-Pls3. Themembrane was incubatedwith anti-PLS3 antibody. (B) Bodyweight growth in SMND7
injected with AAV9-Pls3 (n = 7), AAV9-GFP (n = 7), or PBS controls (n = 7). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; AAV9-Pls3 versus AAV9-GFP; two-way ANOVA
with Dunnett’s multiple comparisons test. (C) Kaplan-Meier survival plot to compare lifespan between all experimental groups of mice (n = 7 per group; overall log-rank test
p < 0.05 between all three groups; pairwise comparisons with Bonferroni correction *p < 0.05 between PLS3 and PBS and #p < 0.05 between PLS3 and GFP). (D) AAV9-Pls3
transduction efficiency in spinal motor neurons. Carrier littermate pups were injected at postnatal day 1 with AAV9-Pls3; spinal cords were extracted at 4 weeks postinjection.
The cervical and lumbar spinal cord sections were fixed and labeled with calcitonin gene-related peptide (CGRP) antibody as amotor neuronal marker (red), PLS3 antibody as
an indicator of transduction (green), and DAPI for visualization of nuclei. Scale bar, 20 mm.
www.moleculartherapy.orgregions: cervical, thoracic, and lumbar spinal cord. The analysis sum-
marized in Figure 4A demonstrates clear PLS3 overexpression in
AAV9-Pls3-treated animals compared to GFP controls. A very
weak band was seen in the control group injected with AAV9-GFP,
indicating cross-species reactivity between the human anti-PLS3 anti-
body and the endogenous mouse PLS3; however, this was used as the
baseline of PLS3 when measuring overexpression.
Our in vivo proof-of-concept study assessed the survival of SMND7
mice following delivery of AAV9 vector-encoding PLS3 (AAV9-
Pls3) into cerebrospinal ﬂuid (CSF). P1 SMND7 KO pups were
injected with 5 mL of AAV9-Pls3 containing 5  1010 vg (n = 7)
into the cisterna magna. As a control, a second group of SMND7
KO mice was treated with AAV9-GFP (5  1010 vg) (n = 7), and a
third group of animals injected with PBS (n = 7). Daily assessment
of the mice was performed throughout their life to determine whetherMolecthere was any effect on SMND7 mouse phenotype. We report a sig-
niﬁcant difference in body weight between AAV9-Pls3-treated group
when compared to AAV9-GFP and PBS controls (p < 0.001) (Fig-
ure 4B). Kaplan-Meier analysis demonstrated that PLS3-treated
mice had longer survival time compared to both untreated and
GFP-treated groups (Figure 4C; p < 0.05). Overall, this study revealed
a marginal but signiﬁcant increase in survival of PLS3-treated mice
compared to controls.
Finally, transduction efﬁciency was assessed to ensure that the
marginal efﬁcacy was not due to inefﬁcient viral vector delivery
to the CNS, in particular to MNs. Cervical and lumbar spinal
cord sections were double-labeled for PLS3 and calcitonin gene-
related peptide (CGRP), previously used as marker for MNs11 (Fig-
ure 4D). PLS3 was detected in motor neurons and neuronal axons,
showing that the virus is targeting motor neurons in the spinalular Therapy: Methods & Clinical Development Vol. 9 June 2018 85
Molecular Therapy: Methods & Clinical Developmentcord (Figure 4D). The PLS3-positive MNs were counted and trans-
duction efﬁciency calculated as the percentage of total CGRP-pos-
itive MNs. Not all CGRP-positive motor neurons expressed PLS3,
instead quantiﬁcation revealed around 29% of motor neurons were
PLS3 positive.
DISCUSSION
SMA is a debilitating fatal childhood neuromuscular disease, charac-
terized by the degeneration of the anterior horn MNs of the spinal
cord due to reduced expression of the SMN protein. In addition to
SMN replacement approaches,12,13 previous studies have reported
other disease-modifying genes, which could also be targeted for
gene-therapy-mediated treatment for SMA, including PLS3, PTEN,
and hnRNP-R.1,9,14,15 Investigation into the function of PLS3 has
begun to shed light on its interaction with SMN and its role in neuro-
protection against SMA. This study aimed to test whether overexpres-
sion of PLS3 by viral-mediated gene therapy could rescue neuronal
loss and increase survival of an SMA mouse model and whether it
could ultimately be considered for potential clinical therapy.
PLS3 Levels in the SMND7 SMA Mouse Model
Our expression proﬁle study revealed that Pls3 is expressed in
neuronal cells in the brainstem and in spinal MNs. Its distribution
was as expected in the spinal cord, being expressed in cell bodies of
MNs and the white matter where the axons of the neurons are
located. This aligns with previous observations that Pls3 co-localizes
with Smn in granules throughout motor neuron axons.1 If both pro-
teins are co-localized, they may have the ability to interact. They
could inﬂuence each other’s stability, which has also been suggested
by other groups.3
Our data conﬁrmed differential Pls3 expression between Smn KO
mice from the SMND7 line and their wild-type littermates. At birth,
there was no difference in Pls3 expression between the genotypes;
however, by end-stage of the disease (P10) the KO animals showed
signiﬁcantly reduced or absent Pls3 protein in both CNS and muscles
when compared to wild types. Carrier mice also showed lower Pls3
levels in the spinal cord, although not in brain or muscles, suggesting
that Smn protein levels are inﬂuencing Pls3 expression in some tis-
sues. This supports previous reports of Pls3 downregulation in the
brain and spinal cord of other SMA animal models and in human
patients.16 This report provides evidence that the SMND7 mouse is
a good model for testing whether modulation of PLS3 can be used
as a gene therapy for SMA.
The molecular mechanisms for PLS3’s involvement in SMA are un-
clear; there are no structural or sequence similarities between SMN
and PLS3 that may suggest they are functionally related, but several
theories have been proposed. PLS3 overexpression has been demon-
strated to increase levels of F-actin, and it has been suggested that its
role in stabilizing actin ﬁlaments is crucial to axon development and
therefore rescue of SMA pathology. However, the effects of expressing
a set of partial Pls3 molecules in zebraﬁsh support a mechanism for
PLS3 in SMA beyond that of actin binding.486 Molecular Therapy: Methods & Clinical Development Vol. 9 June 201Overexpression of PLS3 by Viral Vectors
This study has demonstrated that successful cloning of human Pls3
cDNA into LV or AAV viral vectors was able to signiﬁcantly overex-
press PLS3 protein by at least 5-fold, in vitro and in vivo. In vitro,
overexpression of PLS3 does not appear to be toxic to cells. In addi-
tion, LV-mediated expression of PLS3 in cells lacking Smn rescued
the axonal length deﬁcit. Administration of AAV9-Pls3 to the CNS,
via cisterna magna, in postnatal day 1 SMND7 mice, led to signiﬁcant
spinal MN transduction efﬁciency and extension of SMND7 mouse
lifespan. Although PLS3 overexpression induced small but signiﬁcant
extension in SMND7 mouse survival, this gene transfer strategy did
not lead to noticeable amelioration of the SMA phenotype. It is worth
highlighting that AAV9 administered in P1 pups showed extensive
neuronal tropism. Previous studies have shown that astrocytes from
SMA-induced pluripotent stem cells and in SMND7 mouse spinal
cord exhibit cellular and morphological changes as an indicator of
activation before obvious MN loss.17 Our in vivo data and the later
reports indicate therefore that early disruption of astrocytes may
contribute to SMA disease pathology, which suggests that targeting
both MNs and glial cells may be needed for an effective therapy
in SMA.
The marginal effect of PLS3 gene transfer in a SMA mouse model
could be explained by various factors: (1) SMND7 mouse model dis-
plays severe phenotype with short lifespan. The timing of vector
application is therefore critical for SMA therapy development. It is
likely that AAV-mediated gene transfer would require early start of
therapeutic gene expression. However, this was not the case when us-
ing single-stranded DNA AAV9 in our study. Future efforts could
look at reducing the size of PLS3 to ﬁt the packaging capacity of
self-complementary AAV. This could be achieved by identiﬁcation
of the short gene fragment that could lead to full-length protein
expression. (2) It is widely reported that motor neurons and other
cell types are affected by SMA. Several reports challenge the notion
that SMA is solely a disease of motor neurons and demonstrate
peripheral organ defects and malfunction in association with SMN
deﬁciency.18–20 Thus, the choice of route of delivery such as systemic
could be important for optimal efﬁcacy. (3) The key feature of SMA is
the loss of SMN, which is not addressed by overexpression of PLS3.
PLS3 may be able to rescue some SMN functions but not all, such
as calcium dysregulation, snRNP assembly, and neuronal develop-
ment, which has been reported to be implicated in SMA.17 This, along
with the previous observation in humans, where PLS3 provides full
protection against SMA only in SMN1-deleted individuals carrying
three to four SMN2 copies, but not in those with only two SMN2
copies or less, suggests that certain amount of SMN is required in or-
der to beneﬁt from PLS3 overexpression in individuals lacking SMN1.
In summary, evidence has been provided supporting the role of PLS3
in the pathology of SMA, and restoration of PLS3 expression using a
LV can rescue the axonal phenotype in Smn-deﬁcient cultured motor
neurons. Consistent with recent study,21 we report here that AAV9-
mediated PLS3 overexpression can improve the survival of SMND7
mouse model of SMA. The use of PLS3 overexpression to extend8
www.moleculartherapy.orgSMND7 lifespan demonstrates that PLS3 is a disease modiﬁer of
SMA. PLS3 is a potential therapeutic target and can be used in a
gene therapy approach but maybe required to be delivered in combi-
nation with other disease modulators to give meaningful rescue to
SMA and alleviate the disease phenotype.
MATERIALS AND METHODS
Breeding and Genotyping of Transgenic Mice
Triple mutant mice (FVB.Cg-Tg [SMN2*delta7] 4299Ahmb Tg
[SMN2]89Ahmb Smn1tm1Msd/J SMND7 mice) were used for all
in vivo studies. SMND7 mice were purchased from The Jackson Lab-
oratory (stock #005025) and were maintained in a controlled facility
in a 12-hr dark/12-hr light photocycle (on at 7 a.m./off at 7 p.m.) with
free access to food and water. Carrier (SMD7+/+; SMN2+/+; Smn+/)
animals were used for breeding and the offspring were genotyped
immediately after birth at postnatal day 1 (P1) by PCR ampliﬁcation
of the transgenes according to the protocols provided by The Jackson
Laboratory. The mice are lacking the murine Smn gene (Smn/),6
but they have two transgenes inserted, a copy of the human SMN
gene lacking exon 7 (SMD7) and the full-length human SMN2 gene
(SMN2+/+). SMND7 copy number was veriﬁed as previously
described.6 Offspring (SMD7+/+; SMN2+/+; Smn/) from the same
breeding pair were allocated randomly to the experimental groups.
Viral vectors (AAV9-PLS3 or AAV9-GFP; 5 1010vg) were delivered
via cisterna magna in P1 pups. All in vivo experiments were regulated
under the UKHome Ofﬁce Animals (Scientiﬁc Procedures) Act 1986.
Western Blotting
Brain, spinal cord, and muscle tissues from SMND7 mice were
homogenized in radioimmunoprecipitation assay (RIPA) buffer
(5% Tris-HCl [pH 7.]), 1% NP-40, 0.5% Sodium deoxycholate,
0.01% SDS, 150 mM NaCl, 0.2 mM EDTA) supplemented with 1%
protease inhibitor cocktail (Sigma-Aldrich, S8830). Subsequently, to-
tal protein concentrations were determined using the BCA Protein
AssayKit (Pierce, 23225) according to themanufacturer’protocol. De-
natured proteins samples (20 mg protein/sample) were separated by
electrophoresis on 12% SDS-PAGE and transferred onto a polyvinyli-
dene diﬂuoride (PVDF) membrane (Bio-Rad). The membranes were
probed with the following primary antibodies: polyclonal rabbit
anti-mouse PLS3 ARP56623_P050 PLS3 antibody-middle region
(Aviva, 1/500), mouse anti-glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH; Sigma-Aldrich, 1/1,000). Secondary antibodies were
goat anti-rabbit immunoglobulin (Ig) (DakoCytomation, P0214,
1/1,000) and goat anti-mouse IgG (DakoCytomation, P0448,
1/10,000). Signals were detected using chemiluminescence reagent
(Super Signal West Pico, Pierce) according to standard protocols.
Densitometry of the signals was measured using Chemilmager soft-
ware. Values were normalized to the average of the reference proteins
(GAPDH) from the same mouse. At least three replicates were per-
formed for each sample.
Immunohistochemistry
Animals were terminally anesthetized with pentobarbital and then
transcardially perfused with PBS followed by 4% paraformaldehydeMolecin PBS. Tissues were then postﬁxed for 24 to 48 hr in paraformalde-
hyde at 4C. Brains and spinal cords were then cryoprotected in 30%
sucrose for at least 24 hr at 4C and mounted in optimal cutting
temperature compound (OCT) (Fisher Scientiﬁc, 14-373-65). Tissue
sections of 20-mm thickness were prepared on a sliding cryostat
microtome (Leica) and collected onto gelatin-coated microscope
slides. Immunohistochemistry was then performed with rabbit anti-
body to PLS3 (1:50; Abcam) followed by Alexa Fluor 568 goat anti-
rabbit IgG (1:1000; Invitrogen A11036).
Primary Motor Neuron Culture
Primary motor neurons were puriﬁed from lumbar spinal cords of
embryonic day 13 (E13) mouse embryos and cultured at 37C with
5% CO2 at 95% humidity. In brief, 10 mm coverslips were coated
with 5% poly-DL-ornithine hydrobromide (PORN) (Sigma, P8638)
overnight, washed with Hank’s Balanced Salt Solution (HBSS)
(Sigma, H8264) then coated with 2.5mg/mL Laminin (Invitrogen,
23017-015) in incubator at 37C with 5% CO2 at 95% humidity. Em-
bryos were collected at E13 after sacriﬁcing pregnant mice by cervical
dislocation. Dissection buffer Beta-Mercaptoenthanol—10 nM con-
centration 1:1,000 (b-ME) (Invitrogen, 313500) in HBSS, was used
to place the extracted spinal cords. The cells were suspended for
15 min at 37C with 0.1% trypsin, Worthington 3 crystallized, dis-
solved in HBSS with NaOH added to adjust the pH and ﬁltered
through a 0.22 mm sterile ﬁlter, (Worthington, TLR3-3707). Trypsin
inhibitor—Sigma, 500 mg dissolved in 49 mL HBSS and 1ml of 1 M
HEPES (Sigma, T-6522) and ﬁltered through a 0.22 mm sterile ﬁlter
then was used to deactivate trypsin.
In order to select motor neurons, P75 panning antibody—p75 NGF
receptor antibody (Abcam, ab8877) monoclonal antibody against
extracellular domain of p75 was used at a concentration of 1:5,000
in 10mMTris (pH 9.5) to precoat the plate before placing the cell sus-
pension in order to speciﬁcally select motor neurons. The primary
motor neurons were detached by depolarizing solution (30mM KCl
[Sigma, P9333] + 0.8% NaCl [Sigma-Aldrich, S7653]), while the un-
attached cells were washed off with (Neurobasal medium [NB me-
dium] GIBCO [Invitrogen], with 0.2 mM b-ME). The primary motor
neurons were plated on the precoated coverslips at concentration of
2,000–5,000 cells/coverslip in GIBCO NB supplemented with 2% of
B27 (GIBCO, 12587-010), 1% glutamax (GIBCO, 35050), 2% (v/v)
horse serum donor (Linaris, SHD3250YK), 100 U/mL of penicillin
and 100 mg/mL streptomycin, 0.2 mM b-ME, and 0.5 mM L-gluta-
mine (GIBCO, 35050) and incubated for 24 hr before transduction.
Cells were incubated at 37C in a humidiﬁed incubator with 5% CO2.
Construction and Production of AAV-PLS3 Vectors
A single-stranded DNA AAV plasmid AAV expressing PLS3 was
generated by extracting the PLS3 gene from pcDNA3.1-PLS3-V5/
His6 vector and cloning into pAAV cytomegalovirus (CMV)multiple
cloning site (MCS). First, PLS3 was PCR ampliﬁed using the following
primers: PLS3-EcoRI-forward, GATGCC GAATTC CAG CGTGCC
ACC ATGGAT GAGATGGCT ACCACT, and PLS3-XbaI-reverse,
AGCAA TCTAGA TTA CAC TCT CTT CAT TCC C. The PCRular Therapy: Methods & Clinical Development Vol. 9 June 2018 87
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subcloned into EcoRI-XbaI digested pAAV CMV MCS vector.
High-titer AAV9 vectors were then prepared using a three-plasmid
transient co-transfection system involving a plasmid encoding the
Rep2Cap9 sequence (pAAV2/9), a helper plasmid (pHelper, Strata-
gene) and the vector genomes (AAV-GFP or AAV-PLS3) as previ-
ously described.22,23 AAV9 titers were evaluated by quantitative
PCR assays using primers directed against GFP and linearized
AAV-GFP as a standard curve.22,23
In Vivo Studies
All mouse experiments were approved by the University of Shefﬁeld
Ethical Review Sub-Committee and the UKAnimal Procedures Com-
mittee (London, UK) and performed according to the Animal (Scien-
tiﬁc Procedures) Act 1986, under the Project License 40/3739.
SMND7 mice were purchased from The Jackson Laboratory (stock
#005025) and were maintained in a controlled facility in a 12-hr
dark/12-hr light photocycle (on at 7 a.m./off at 7 p.m.) with free access
to food and water. Carrier (SMD7+/+; SMN2; Smn+/) animals were
used for breeding, and the offspring were genotyped immediately
after birth at postnatal day 1 (P1) by PCR ampliﬁcation of the trans-
genes according to the protocols provided by The Jackson Laboratory.
SMND7 copy number was veriﬁed as previously described.6 Offspring
(SMND7+/+; SMN2; Smn/) from the same breeding pair were allo-
cated randomly to the experimental groups. Viral delivery was
achieved as previously reported.23 In brief, AAV9-PLS3 (n = 7) or
AAV9-GFP (n = 7) was administered via cisterna magna in postnatal
day 1 pups. 5  1010 vg of viral vector solution was injected to each
animal using a 33-gauge Hamilton syringe (ESS Lab). The animals
were left to recover before being rolled in sawdust from their cage
and returned to the cage with their mother.
Design and Production of LV
A LV expressing PLS3 was generated by extracting the PLS3 gene
from pcDNA3.1-PLS3-V5/His6 Vector, provided by Prof. Brunhilde
Wirth, (University Hospital of Cologne, Germany) and cloning into
the LV backbone (SIN-PGK-cPPT-WHV; kindly provided by
Dr. Nicole Deglon). Double digestion for all the samples with BamHI
and XhoI restriction enzymes conﬁrmed the presence of the insert.
In addition, sequencing of the insert was achieved using primers tar-
geted to PGK promoter: PGK forward, 50- GGGAATTCCGATAAT
CAAC-30 and PGK reverse, 50-CCTTCGCTTTCTGGGCTCA-30.
The sequencing conﬁrmed the correct orientation of the insert.
LV production was achieved as previously described.24 In brief,
3  106 HEK293T cells were transfected after 24 hr of plating with
a mix of four plasmids: pMD.2G: plasmid encoding the vesicular sto-
matitis virus G (VSV-G) envelope, pCMVDR8.92; packaging plasmid
encoding all the viral genes needed in trans, SIN-W-PGK; transfer
plasmid containing (PLS3) and pRSV-Rev; plasmid encoding the
rev protein of human immunodeﬁciency virus (HIV)-1. Viral
production was performed as previously described.24 At 72 hr post-
transfection, the viral supernatant was harvested, ﬁltered through
0.45 mm ﬁlter and concentrated by ultracentrifugation for 90 min at88 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20119,000 rpm and at 4C. The viral pellet was suspended in 1.8 mL
PBS supplemented with 1% BSA (Sigma), divided into 50 mL aliquots
and stored at 80C. Finally, LV titration was performed by Enzyme
Linked Immunosorbent Assay (ELISA) which targets HIV-1 p24 an-
tigen (ZMC No. 0801111, ZeptoMetrix Corporation).
In Vitro Transduction and Immunostaining of Primary Motor
Neurons
Primary motor neurons were isolated at E13 from SMA (Smn+/+;
SMN2+/+; Smn/) and carrier littermate (Smn+/+; SMN2+/+;
Smn+/) embryos. Twenty-four hours after plating, MNs were trans-
duced with LV-PLS3 or LV-GFP virus at an MOI of 5, 10, 20, 40, and
80 for immunocytochemistry. Transduction efﬁciency was assessed
by counting the GFP-positive cells under the ﬂuorescence microscope
after transduction with LV-GFP and was found to be 70%–80% at an
MOI of 40. Plates were incubated at 37C and 5% CO2 for 7 days and
immunostained with anti-Tubulin and anti-Pls3. Double staining
with anti-tubulin 1:500 and anti-Pls3 1:500 was performed overnight.
Then the secondary antibodies were then added at 1:200 for 2 hr
at RT: goat anti-rabbit A568 Alexa red (Pls3), goat anti-mouse
A350 blue (Tubulin). Images were taken by confocal microscope.
The axon length was measured by ImageJ plugin NeuronJ.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism 6. Statistical
signiﬁcance was assessed with one- or two-way ANOVA. A value of
p < 0.05 was considered to be statistically signiﬁcant.
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